161 | I expect huge activity for next 10 days.I'm sure | stockangele | 01/03/2013 11:18:50 AM |
160 | Thank you for info. I'm sure, we will see | stockangele | 01/03/2013 11:12:55 AM |
159 | RLIA wi | stockangele | 01/03/2013 11:05:21 AM |
158 | It could be said that in the future we can see | stockangele | 01/03/2013 10:57:35 AM |
157 | This me | duncanluger | 01/03/2013 6:16:36 AM |
156 | Whoa, t | duncanluger | 01/03/2013 6:14:19 AM |
155 | Thnx fo | duncanluger | 01/03/2013 6:09:37 AM |
154 | Cant wa | duncanluger | 01/03/2013 6:07:32 AM |
153 | Amazing | duncanluger | 01/03/2013 6:04:44 AM |
152 | RLIA @ Support & Resistance point!!!! | Mary Johnson | 01/03/2013 5:06:25 AM |
151 | TDD and Low analysis - Bu signals!!!! | Mary Johnson | 01/03/2013 5:03:17 AM |
150 | I am no | Mary Johnson | 01/03/2013 4:59:51 AM |
149 | New tra | Mary Johnson | 01/03/2013 4:56:28 AM |
148 | We saw | Mary Johnson | 01/03/2013 4:54:04 AM |
147 | Nearly | mwirmm | 01/02/2013 3:59:41 PM |
146 | No move | mwirmm | 01/02/2013 3:59:38 PM |
145 | thats e | mwirmm | 01/02/2013 3:59:35 PM |
144 | 700% is | mwirmm | 01/02/2013 3:59:32 PM |
143 | This go | mwirmm | 01/02/2013 3:59:29 PM |
142 | That's | theellasmith | 01/02/2013 3:04:25 PM |
141 | On a sh | theellasmith | 01/02/2013 3:02:34 PM |
140 | RLIA - | theellasmith | 01/02/2013 2:58:34 PM |
139 | RLIA - | theellasmith | 01/02/2013 2:55:50 PM |
138 | RLIA - | theellasmith | 01/02/2013 2:53:57 PM |
137 | For a short time, they have show that they are | stockangele | 01/02/2013 11:53:29 AM |
136 | They de | stockangele | 01/02/2013 11:33:46 AM |
135 | Amazing | stockangele | 01/02/2013 11:28:19 AM |
134 | Happy new year too. I'm sure that indicator will | stockangele | 01/02/2013 11:10:31 AM |
133 | I follo | stockangele | 01/02/2013 10:58:20 AM |
132 | 2013. w | duncanluger | 01/02/2013 6:14:57 AM |
131 | You are | Mary Johnson | 01/02/2013 6:07:56 AM |
130 | Tnx, it | duncanluger | 01/02/2013 6:07:43 AM |
129 | The des | John Howard | 01/02/2013 6:06:04 AM |
128 | It looks nice, and design is quite innovative. | duncanluger | 01/02/2013 6:02:56 AM |
127 | Me too, | John Howard | 01/02/2013 6:02:25 AM |
126 | Thank y | Mary Johnson | 01/02/2013 6:00:47 AM |
125 | Happy new year too.The beginning of a new year is | Mary Johnson | 01/02/2013 5:57:41 AM |
124 | Well of | duncanluger | 01/02/2013 5:56:12 AM |
123 | Wow up | Mary Johnson | 01/02/2013 5:55:51 AM |
122 | Incredible...Tnx for posting | Mary Johnson | 01/02/2013 5:53:01 AM |
121 | RLIA grabs forward | duncanluger | 01/02/2013 5:52:28 AM |
120 | How much money could have RLIA made you in 2012 | John Howard | 01/02/2013 5:30:34 AM |
119 | RLIA Awards | John Howard | 01/02/2013 5:23:05 AM |
118 | RLIA Pr | John Howard | 01/02/2013 5:15:17 AM |
117 | RLIA is up!!!!As we predicted RLIA is up by | Mary Johnson | 12/28/2012 3:49:52 PM |
116 | I guess | Mary Johnson | 12/28/2012 3:04:44 PM |
115 | Well im | Mary Johnson | 12/28/2012 3:01:06 PM |
114 | I was r | Mary Johnson | 12/28/2012 2:47:36 PM |
113 | Great j | Mary Johnson | 12/28/2012 2:44:34 PM |
112 | You are | Mary Johnson | 12/28/2012 2:41:32 PM |
Recent Articles
- Established Tech Giants Poised to Lead in AI Development
- ENGWE's Innovative Journey: Connecting E-Bike Riders Worldwide
- Investigation Ongoing After Daring Jewelry Heist at Louvre
- Unveiling Sustainable Solutions: Insights from Global Leaders
- SKYWORTH Launches Revolutionary Matte Screen Ultra TV Series
- Exciting Advances in Lung Cancer Treatment with Sacituzumab Tirumotecan
- MoonLake Immunotherapeutics: A Call to Action for Investors
- Investors Urged to Act Quickly in PubMatic Class Action Suit
- Tragic Cargo Plane Incident at Hong Kong Airport Sparks Concerns
- Christine Lagarde's Insight: Upcoming Tariff Effects on U.S. Consumers
- Insights on the Upcoming Financial Street Forum in Beijing
- Antengene Advances ATG-022: Promising Clinical Outcomes Revealed
- Investigation Announcement for Baxter International Investors
- Cytokinetics Investors: Secure Representation Before Deadline
- Jasper Therapeutics Investors: Important Class Action Deadline Ahead
- Mesoblast Limited Reports Significant Revenue Growth After Ryoncil Launch
- CStone Pharmaceuticals Shares Promising Phase I Results for CS2009
- Ascletis Completes Enrollment in Phase IIa Study of ASC30.
- Innovations in Pancreatic Cancer Treatment with Satri-cel
- Cambodia's Techo International Airport: A Gateway to Growth
- Record Growth in Q2 Revenues Enhances Mesoblast's Market Position
- Faraday Future's Vision: Accelerating Towards FX Super One Launch
- IZERVAY™ Delivers Long-Term Benefits for Geographic Atrophy Patients
- Clover Biopharmaceuticals Names Nicholas Jackson as President
- Dr. Luke Wainscoat Brings Expertise to The Brattle Group
- Kering and L'Oréal Unite to Transform Luxury Beauty Sector
- Kering and L’Oréal: A New Era in Luxury Beauty and Wellness
- Kering Partners with L'Oréal to Transform Luxury Beauty Sector
- Alice Walton and Elon Musk: Giants of Wealth in 2025
- Clarins and V Magazine Host a Glamorous Golden Hour Event
- Sobi Adjusts Revenue Forecast for 2025 Amid Strong Q3 Growth
- Sobi Updates Full-Year Outlook and Q3 2025 Financial Report
- Exploring NB HASH and the Transformation of Wealth Today
- Kevin Hart's Journey From Investment Missteps to Business Success
- BlackRock's Strategic Shift: The Future of Investment in RWA
- Major Contract Termination Announced by Vantage Drilling
- Deadline Approaches for Dow Inc. Investors Amid Legal Action
- Important Update for Cepton, Inc. Investors on Class Action
- Target and Walmart Thrive Amid Collectible Card Sales Surge
- Snap Investors Urged to Consider Leading Legal Action
- Unlocking Wealth Potential: The RWA Revolution Explained
- Embracing Real-World Assets with NB HASH for Sustainable Growth
- Nutex Health Investors Can Join Class Action Against Company
- Potential Legal Action for Baxter International Investors
- Solidarity in Aviation: Airline Workers Support Controllers
- Class Action Lawsuit Against MoonLake Immunotherapeutics Investors
- Promising Outcomes Unveiled from HARMONi-6 Clinical Study
- Exploring Cadonilimab's Promising Results in Advanced Gastric Cancer
- Tech Giants Reshape Manufacturing Strategies Amid Market Shifts
- Promising Findings on Subcutaneous Amivantamab for Cancer